

## Technology Advisory Committee B Interests Register

**Topic: Abaloparatide for treating osteoporosis in postmenopausal women [ID882]**

**Publication Date: TBC.**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Becky Pennington	TAC A Committee Member	Indirect – Financial	Becky is pursuing some unrelated consultancy work with Eli Lilly in Alzheimer's.	18/04/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.
Eugene McCloskey	Clinical Expert	Direct - Financial	<p>Amgen: Advisory Board and/or Honoraria and/or Research Funding; 2005-Ongoing</p> <p>Consilient Healthcare: Advisory Board and/or Honoraria and/or Research Funding; 2012-2018</p> <p>Eli Lilly: Advisory Board and/or Honoraria ;2005-2020</p> <p>Fresenius Kabi: Advisory Board; 2018-2018</p> <p>Internis; Advisory Board and/or Honoraria and/or Research Funding ;2012-2019</p> <p>ObsEva: Advisory Board and Research Funding ; 2019-2022</p>		It was agreed that Mr McCloskey's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Radius Inc: Advisory Board and/or Honoraria and/or Research Funding; 2014-2021</p> <p>UCB: Advisory Board and/or Honoraria and/or Research Funding; 2010-Ongoing</p>		
Eugene McCloskey	Clinical Expert	Direct – non-financial	<p>Director, Osteoporosis Research Limited; 2021-ongoing</p> <p>Member of IOF Board; 2010-ongoing</p> <p>Member of ESCEO Board; 2010-ongoing</p> <p>Chair of Osteoporosis 2000; 2005-ongoing</p> <p>Past Member of ROS Bone Research Academy (Lead of Effectiveness Working Group); 2018-2022</p>		It was agreed that Mr McCloskey's declaration would not prevent him from providing expert advice to the committee.
Stephen Tuck	Clinical Expert	Indirect - Financial	<p><b>2022</b></p> <p>1.6% of total income was from pharmaceutical companies</p> <p>[Amgen donated £10k to support policy and public affairs work to</p>		It was agreed that Mr Tuck's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>promote fracture liaison services from Jan-Dec 2022</p> <p>UCB donated £10,675 in 2022 for similar work.]</p> <p><b>2023</b></p> <p>UCB donated £49,395 to support as above.</p> <p>In addition, the following are for Stands at a coming Conference for healthcare professionals:</p> <p>UCB £25k</p> <p>Amgen £25k</p> <p>Thornton &amp; Ross £18.5k</p> <p>Flynn Pharma £6k</p> <p>Stirling Anglian Pharma £2k</p> <p>Theramex did not support us in the last 12 months.</p>		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.		
Philippa Russell	Patient Expert	Indirect - Financial	<p><b>2022</b></p> <p>1.6% of total income was from pharmaceutical companies</p> <p>[Amgen donated £10k to support policy and public affairs work to promote fracture liaison services from Jan-Dec 2022</p> <p>UCB donated £10,675 in 2022 for similar work.]</p> <p><b>2023</b></p> <p>UCB donated £49,395 to support as above.</p> <p>In addition, the following are for Stands at a coming Conference for healthcare professionals:</p> <p>UCB £25k</p>		It was agreed that Ms Russell's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Amgen £25k</p> <p>Thornton &amp; Ross £18.5k</p> <p>Flynn Pharma £6k</p> <p>Stirling Anglian Pharma £2k</p> <p>Theramex did not support us in the last 12 months.</p> <p>Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.</p>		
Alison Smith	Patient Expert	Indirect - Financial	<p>2022</p> <p>1.6% of total income was from pharmaceutical companies</p> <p>[Amgen donated £10k to support policy and public affairs work to promote fracture liaison services from Jan-Dec 2022</p> <p>UCB donated £10,675 in 2022 for similar work.]</p>		It was agreed that Ms Smith's declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>2023</p> <p>UCB donated £49,395 to support as above.</p> <p>In addition, the following are for Stands at a coming Conference for healthcare professionals:</p> <p>UCB £25k</p> <p>Amgen £25k</p> <p>Thornton &amp; Ross £18.5k</p> <p>Flynn Pharma £6k</p> <p>Stirling Anglian Pharma £2k</p> <p>Theramex did not support us in the last 12 months.</p> <p>Negotiations are underway for a further £10K from both UCB and Theramex later in 2023.</p>		